Kiranjit Dhillon, MD
Nephrology · Norfolk, VANPI 1598722803
Payments from drug & device makers
Across 556 payments — averaging $8170.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$2.9M
- Vertex$1.2M
- Akebia Therapeutics Inc$137K
- Alnylam Pharmaceuticals Inc.$83K
- Dynavax Technologies Corporation$48K
- Boehringer Ingelheim$39K
- plus $68K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 162 | $2,940,872 |
| Vertex | 7 | $1,226,968 |
| Akebia Therapeutics Inc | 234 | $137,345 |
| Alnylam Pharmaceuticals Inc. | 23 | $82,572 |
| Dynavax Technologies Corporation | 33 | $47,646 |
| Boehringer Ingelheim | 8 | $39,216 |
| Merck | 2 | $33,058 |
| AstraZeneca(2 entities) | 12 | $16,269 |
| Baxter Healthcare | 2 | $14,820 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 6 | $2,808 |
| Amgen(2 entities) | 16 | $322 |
| Vifor Pharma, Inc. | 5 | $130 |
| Bayer | 6 | $91 |
| Calliditas Therapeutics US Inc. | 5 | $79 |
| Travere Therapeutics, Inc. | 11 | $77 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Novartis | 3 | $63 |
| ANI Pharmaceuticals, Inc. | 3 | $53 |
| Aurinia Pharma U.S., Inc. | 2 | $43 |
| Ardelyx, Inc. | 2 | $40 |
| Fresenius USA Marketing, Inc. | 2 | $32 |
| Veloxis Pharmaceuticals, Inc. | 1 | $24 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $23 |
| Nxstage Medical, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| One Lambda, Inc. | 1 | $19 |
| GSK | 1 | $18 |
How this compares
$4,542,743 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Norfolk
- Thomas McCuneNorfolk$386K
- Yury KalmanovichNorfolk$309K
- Sandeep MagoonNorfolk$204K
- Ramin TolouianNorfolk$146K
- Abdul ChaudhryNorfolk$32K
- Wei ZhaoNorfolk$8K
- Olayiwola AyodejiHampton$7M
- Gaurav GuptaRichmond$2.1M
- Csaba KovesdySalem$1.5M
- Ramon MendezWoodbridge$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.